A L Cunningham1, R Taylor, J Taylor, C Marks, J Shaw, A Mindel. 1. Sexually Transmitted Infections Research Centre and University of Sydney, Marian Villa, Westmead Hospital, Westmead, NSW 2145, Australia.
Abstract
BACKGROUND: Studies demonstrating previous herpes simplex virus (HSV) type 2 infection as a risk factor for HIV transmission, and the development of a HSV vaccine candidate, have emphasised the need for worldwide population based studies of HSV seroprevalence. The only nationwide seroprevalence studies have been conducted in the United States. METHODS: An Australia-wide, population based study of HSV-1 and HSV-2 seroprevalence was conducted, using serum and sociodemographic data collected between 1999-2000, for a representative study of risk factors for diabetes in over 11 000 adults. A stratified random sample of 4000 was tested for HSV-2 and 1000 for HSV-1, with sampling and weighting for various demographic factors. RESULTS: Seroprevalence of HSV-2 in Australian adults was 12%. Prevalence in women (16%) was twice that in men (8%). Rural populations had a lower prevalence (9%) than metropolitan (13%), and Indigenous had a higher prevalence (18%) than the non-Indigenous populations (12%). The seroprevalence of HSV-1 was 76% with significant differences by age group, sex and Indigenous status. CONCLUSION: These are the first nationwide data to compare with US studies. HSV-2 infection is less common in Australia than the United States, and this will allow planning for combating HIV transmission in high prevalence populations in northern Australia. In addition, the high HSV-1 seroprevalence will be important for future deployment of genital herpes vaccines.
BACKGROUND: Studies demonstrating previous herpes simplex virus (HSV) type 2 infection as a risk factor for HIV transmission, and the development of a HSV vaccine candidate, have emphasised the need for worldwide population based studies of HSV seroprevalence. The only nationwide seroprevalence studies have been conducted in the United States. METHODS: An Australia-wide, population based study of HSV-1 and HSV-2 seroprevalence was conducted, using serum and sociodemographic data collected between 1999-2000, for a representative study of risk factors for diabetes in over 11 000 adults. A stratified random sample of 4000 was tested for HSV-2 and 1000 for HSV-1, with sampling and weighting for various demographic factors. RESULTS: Seroprevalence of HSV-2 in Australian adults was 12%. Prevalence in women (16%) was twice that in men (8%). Rural populations had a lower prevalence (9%) than metropolitan (13%), and Indigenous had a higher prevalence (18%) than the non-Indigenous populations (12%). The seroprevalence of HSV-1 was 76% with significant differences by age group, sex and Indigenous status. CONCLUSION: These are the first nationwide data to compare with US studies. HSV-2 infection is less common in Australia than the United States, and this will allow planning for combating HIV transmission in high prevalence populations in northern Australia. In addition, the high HSV-1 seroprevalence will be important for future deployment of genital herpes vaccines.
Authors: P Wutzler; H W Doerr; I Färber; U Eichhorn; B Helbig; A Sauerbrei; A Brandstädt; H F Rabenau Journal: J Med Virol Date: 2000-06 Impact factor: 2.327
Authors: N Nzila; M Laga; M A Thiam; K Mayimona; B Edidi; E Van Dyck; F Behets; S Hassig; A Nelson; K Mokwa Journal: AIDS Date: 1991-06 Impact factor: 4.177
Authors: A L Cunningham; F K Lee; D W Ho; P R Field; C L Law; D R Packham; I D McCrossin; E Sjögren-Jansson; S Jeansson; A J Nahmias Journal: Med J Aust Date: 1993-04-19 Impact factor: 7.738
Authors: Edith Nakku-Joloba; Fred Kambugu; Julius Wasubire; Joshua Kimeze; Robert Salata; Jeffrey M Albert; Alfred Rimm; Christopher Whalen Journal: Afr Health Sci Date: 2014-12 Impact factor: 0.927
Authors: Anthony Cunningham; Paul Griffiths; Peter Leone; Adrian Mindel; Rajul Patel; Lawrence Stanberry; Richard Whitley Journal: J Clin Virol Date: 2011-09-01 Impact factor: 3.168
Authors: Sarah Samandary; Hédia Kridane-Miledi; Jacqueline S Sandoval; Zareen Choudhury; Francina Langa-Vives; Doran Spencer; Aziz A Chentoufi; François A Lemonnier; Lbachir BenMohamed Journal: Hum Immunol Date: 2014-05-04 Impact factor: 2.850
Authors: Robert B Belshe; Peter A Leone; David I Bernstein; Anna Wald; Myron J Levin; Jack T Stapleton; Iris Gorfinkel; Rhoda L Ashley Morrow; Marian G Ewell; Abbie Stokes-Riner; Gary Dubin; Thomas C Heineman; Joann M Schulte; Carolyn D Deal Journal: N Engl J Med Date: 2012-01-05 Impact factor: 91.245
Authors: Thomas J Whitford; Stephen J Wood; Alison Yung; Luca Cocchi; Gregor Berger; Martha E Shenton; Marek Kubicki; Lisa Phillips; Dennis Velakoulis; Robert H Yolken; Christos Pantelis; Patrick McGorry; G Paul Amminger Journal: Schizophr Res Date: 2012-01-12 Impact factor: 4.939
Authors: Heather Donaghy; Lidija Bosnjak; Andrew N Harman; Valerie Marsden; Stephen K Tyring; Tze-Chiang Meng; Anthony L Cunningham Journal: J Virol Date: 2008-12-10 Impact factor: 5.103